US Patent

US11938141 — Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Formulation · Assigned to Cassiopea SpA · Expires 2028-07-24 · 2y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a new enzymatic process for making certain compounds, including a new crystalline form of the active ingredient in the drug Winlevi.

USPTO Abstract

The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

Drugs covered by this patent

Patent Metadata

Patent number
US11938141
Jurisdiction
US
Classification
Formulation
Expires
2028-07-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Cassiopea SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.